Page last updated: 2024-10-18
dalteparin and Inborn Errors of Metabolism
dalteparin has been researched along with Inborn Errors of Metabolism in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "This study aimed to compare initiating warfarin at the recommended dosing regimen versus empirically lowered doses intended to account for the variation in warfarin sensitivity." | 3.11 | Comparison of Warfarin Initiation at 3 mg Versus 5 mg for Anticoagulation of Patients with Mechanical Mitral Valve Replacement Surgery: A Prospective Randomized Trial. ( Ahmed, MA; El Wakeel, LM; Sabry, S; Saleh, A, 2022) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Sabry, S | 1 |
| El Wakeel, LM | 1 |
| Saleh, A | 1 |
| Ahmed, MA | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Evaluation of Warfarin Initiation at 3mg Versus 5mg for Anticoagulation of Mechanical Mitral Valve Replacement Patients[NCT04235569] | Phase 4 | 50 participants (Actual) | Interventional | 2018-03-01 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trials
1 trial available for dalteparin and Inborn Errors of Metabolism